<PAGE> 1
ILEX ONCOLOGY, INC.
JUNE 30, 2000 - QUARTERLY REPORT ON FORM 10-Q
--------------------------------------------------------------------------------
EXHIBIT 11.1
COMPUTATION OF NET LOSS PER SHARE
(In Thousands, Except Per Share Amounts)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30,
---------------------- ----------------------
2000 1999 2000 1999
--------- --------- --------- ---------
<S> <C> <C> <C> <C>
COMPUTATION OF BASIC NET LOSS PER SHARE:
Net loss $ (4,544) $ (22,609) $ (7,928) $ (27,089)
========= ========= ========= =========
Weighted average shares of common stock outstanding 24,825 12,916 23,432 12,790
========= ========= ========= =========
Basic net loss per share $ (0.18) $ (1.75) $ (0.34) $ (2.12)
========= ========= ========= =========
COMPUTATION OF DILUTED NET LOSS PER SHARE:
Net loss $ (4,544) $ (22,609) $ (7,928) $ (27,089)
Preferred stock dividends not incurred upon assumed conversion of
preferred stock 75 -- 150 --
--------- --------- --------- ---------
Loss available to common stockholders assuming conversion of
subsidiary's preferred stock $ (4,469) $ (22,609) $ (7,778) $ (27,089)
========= ========= ========= =========
Weighted average number of shares of common stock and common
stock equivalents outstanding-
Weighted average shares of common stock outstanding 24,825 12,916 23,432 12,790
Weighted average number of common stock equivalents applicable to
stock options, warrants and subsidiary's preferred stock 1,125 323 1,219 431
--------- --------- --------- ---------
Common stock and common stock equivalents 25,950 13,239 24,651 13,221
========= ========= ========= =========
Diluted net loss per common stock and common stock equivalents (a) $ (0.17) $ (1.71) $ (0.32) $ (2.05)
========= ========= ========= =========
</TABLE>
(a) This calculation is submitted in accordance with Item
601(b)(11) of Regulation S-K although it is not required by
SFAS No. 128 because it is antidilutive.
19